» Articles » PMID: 35439359

Characterization of KIR NK Cell Subsets with a Monoclonal Antibody Selectively Recognizing KIR2DL1 and Blocking the Specific Interaction with HLA-C

Abstract

The phenotypic identification of different NK cell subsets allows more in-depth characterization of KIR repertoire and function, which are of potential interest in KIR and disease association studies. KIR genes are highly polymorphic, but a great homology exists among the various sequences and few monoclonal antibodies (mAbs) specifically recognize a single KIR. This is the case of HP-DM1 which was demonstrated by analysis of cell transfectants and epitope mapping to be exclusively KIR2DL1-specific, covering all allotypes identified to date, except for KIR2DL1*022 and *020, and also to react with KIR2DS1*013. Here, we compared in immunofluorescence analyses the staining of HP-DM1 with other available mAbs to precisely identify KIR2DL1 NK cells in potential donors for αβT/B-depleted haplo-HSCT, with known KIR genotype. HP-DM1 mAb was used in combination with EB6 or 11PB6 (anti-KIR2DL1/S1 and anti-KIR2DL3*005), 143211 (anti-KIR2DL1/S5), and HP-MA4 (anti-KIR2DL1/S1/S3/S5) mAbs, allowing the accurate identification of different KIR NK cell subsets. These phenotypic evaluations appeared useful to dissect the expression pattern of various KIR2D in NK cells from KIR2DL3*005 individuals, particularly if KIR2DS1 is present. HP-DM1 mAb remarkably refined NK cell phenotyping of donors carrying KIR2DS5, either in the centromeric or telomeric region. Functional assays with KIR2DL1 /S1 /S5 NK cells confirmed that only HP-DM1 exclusively reacts with KIR2DL1. Finally, we demonstrated that HP-DM1 mAb blocked KIR2DL1 recognition of C2 HLA-C. Altogether, the data support that HP-DM1 is a unique reagent valuable for characterizing KIR NK cell subsets.

Citing Articles

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.

Meazza R, Ruggeri L, Guolo F, Minetto P, Canevali P, Loiacono F Front Immunol. 2023; 14:1111419.

PMID: 36865545 PMC: 9971917. DOI: 10.3389/fimmu.2023.1111419.


Relevant biomarkers of kidney allograft rejection.

Loga L, Dican L, Matei H, Maruntelu I, Constantinescu I J Med Life. 2022; 15(11):1330-1333.

PMID: 36567832 PMC: 9762359. DOI: 10.25122/jml-2022-0181.


Roles of platelets in tumor invasion and metastasis: A review.

Bian X, Yin S, Yang S, Jiang X, Wang J, Zhang M Heliyon. 2022; 8(12):e12072.

PMID: 36506354 PMC: 9730139. DOI: 10.1016/j.heliyon.2022.e12072.


Characterization of KIR NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C.

Meazza R, Falco M, Canevali P, Loiacono F, Colomar-Carando N, Muntasell A HLA. 2022; 100(2):119-132.

PMID: 35439359 PMC: 9543057. DOI: 10.1111/tan.14640.


Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes.

Falco M, Meazza R, Alicata C, Canevali P, Muntasell A, Bottino C HLA. 2022; 100(2):107-118.

PMID: 35411634 PMC: 9544867. DOI: 10.1111/tan.14630.

References
1.
Fan Q, Long E, Wiley D . Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol. 2001; 2(5):452-60. DOI: 10.1038/87766. View

2.
Manser A, Scherenschlich N, Thons C, Hengel H, Timm J, Uhrberg M . KIR Polymorphism Modulates the Size of the Adaptive NK Cell Pool in Human Cytomegalovirus-Infected Individuals. J Immunol. 2019; 203(8):2301-2309. DOI: 10.4049/jimmunol.1900423. View

3.
Vivier E, Raulet D, Moretta A, Caligiuri M, Zitvogel L, Lanier L . Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-9. PMC: 3089969. DOI: 10.1126/science.1198687. View

4.
Cisneros E, Moraru M, Gomez-Lozano N, Muntasell A, Lopez-Botet M, Vilches C . Haplotype-Based Analysis of -Gene Profiles in a South European Population-Distribution of Standard and Variant Haplotypes, and Identification of Novel Recombinant Structures. Front Immunol. 2020; 11:440. PMC: 7089957. DOI: 10.3389/fimmu.2020.00440. View

5.
Steiner N, Dakshanamurthy S, Nguyen N, Hurley C . Allelic variation of killer cell immunoglobulin-like receptor 2DS5 impacts glycosylation altering cell surface expression levels. Hum Immunol. 2013; 75(2):124-8. PMC: 3924325. DOI: 10.1016/j.humimm.2013.11.012. View